医学
狼牙棒
危险系数
血脂异常
内科学
疾病
冠状动脉疾病
置信区间
入射(几何)
心脏病学
血管疾病
前瞻性队列研究
血压
糖尿病
心肌梗塞
经皮冠状动脉介入治疗
内分泌学
物理
光学
作者
Guillermo Escudero-Sánchez,Sergio Rico‐Martín,Carmen Sánchez‐Bacaicoa,Clara Costo,Javier Galán‐González,Julián Fernando Calderón García,Juan D. Pedrera‐Zamorano,Juan Francisco Sánchez Muñoz-Torrero
标识
DOI:10.1016/j.cpcardiol.2022.101530
摘要
The effects of maintaining all classical, vascular risk factors on target among patients with stabilized atherosclerotic cardiovascular disease (ASCVD) are uncertain. Factores de Riesgo y ENfermedad Arterial (FRENA) was a prospective registry of consecutive outpatients with coronary, cerebrovascular, or peripheral artery disease. We analyzed the incidence of recurrent events and mortality according to sustained, optimal control of principal risk factors including the following: LDL cholesterol, glucose, blood pressure, and smoking. As of December 2018, 4285 stable outpatients were eligible for this study. Over a median follow-up of 21 months, 664 (15%) maintained all risk factors on target (Group 1), while 3621 (85%) did not (Group 2). During follow-up, no differences in recurrent major adverse cardiovascular events (MACEs) or death were observed between groups. On multivariable analysis, patients with previous known dyslipidemia (hazard ratio [HR]: 95% confidence interval (95% CI): ([HR]: 1.20 [95% CI, 1.03-1.40]), polyvascular disease ([HR]: 1.98 [95% CI, 1.69-2.32]), insulin therapy ([HR]: 1.56 [95% CI, 1.24-1.95]) and associated conditions ([HR]: 1.47 [95% CI, 1.24-1.74]) were associated with a higher risk for subsequent MACE. The presence of associated medical conditions was also strongly associated with all-cause death ([HR]: 3.49 [95% CI, 2.35-5.19]). Only a minority of patients with atherosclerotic cardiovascular disease achieved sustained optimal control for all principal risk factors although without discernible clinical, therapeutic benefit. The findings of the present study provide some insights into what factors may be used to guide physicians in adapting intensive, multifactorial therapy to the individual patient in clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI